淋巴瘤
CD19
流式细胞术
基因重排
癌症研究
免疫分型
B细胞
CD38
抗原
CD20
生物
弥漫性大B细胞淋巴瘤
抗体
分子生物学
基因
免疫学
遗传学
干细胞
川地34
作者
Diana Mandelker,David M. Dorfman,Betty Li,Olga Pozdnyakova
标识
DOI:10.3109/10428194.2013.879714
摘要
B-cell lymphomas with MYC rearrangement are a heterogeneous and unique group of neoplasms that may behave aggressively, especially in conjunction with other oncogenic alterations that cooperate with MYC, warranting early and intensive treatment in a subset of patients. Identification of MYC-rearranged B-cell lymphomas by immunophenotypic analysis could help guide cytogenetic work-up, as well as expedite therapeutic interventions. Using flow cytometry we analyzed the expression of CD10, CD19, CD20, CD38 and CD45 in 53 patients with three distinct neoplasms with MYC rearrangements: Burkitt lymphoma (n = 12), double hit lymphoma (n = 17) and diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (n = 8). The expression profile of these commonly used antibodies was similar among these three groups. The antigenic pattern of bright CD38 and dim CD45 was unique to the MYC-rearranged neoplasms when compared to non-MYC-rearranged aggressive DLBCL (n = 16), with a combined sensitivity of 67% and specificity of 100%, suggesting a shared underlying biology among these MYC rearranged B-cell lymphomas.
科研通智能强力驱动
Strongly Powered by AbleSci AI